On the 50 th Anniversary of the First Heart Transplantation The founder of experimental and clinical transplantation in cardiosurgery is Norman Shumway. This fact is irrefutable and unconditional. This is known and has been recognized by everyone, and that’s why the

This article specially prepared for the Journal “Clinical and Experimental Surgery”, is the slightly modified manuscript from the American Transplant Society’s Textbook. Much of the text has been published in the Chapter by R.Y. Calne in the Textbook of

This original article was written at the request of Sergei Dzemeshkevich (sdzemeshkevich@gmail.com) and has never been published before, July 13, 2017. Heart transplantation Historical Note   The year 2017 marks the 50th anniversary of one of the most dramatic

Technical advances in the field of left ventricular assist devices (VAD) offer solutions that are not only about survival but also about improving the quality of patients’ life in time of donor scarcity [1]. Possibly, VADs can replace heart transplantation (HTx)

Heart transplantation is the treatment of choice for patients with end-stage heart disease [1-3]. However, heart transplantation has a high early mortality, mostly attributable to donor organ failure [4]. Under conventional conditions of donor organ preservation, prolonged

RAS proteins bound to certain enzymes, including RAS mitogen-activated protein kinase (MAPK), provide regulation of signal transduction, control cellular proliferation, differentiation and survival. RASopathies are group of syndromes caused by mutations in various genes of